相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High activation of STAT5A drives peripheral T-cell lymphoma and leukemia
Barbara Maurer et al.
HAEMATOLOGICA (2020)
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
Peter C. Taylor
RHEUMATOLOGY (2019)
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation
Alexandra Gomez-Arteaga et al.
LEUKEMIA & LYMPHOMA (2019)
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp B. Staber et al.
BLOOD (2019)
Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects
Daniele Mannina et al.
DRUGS (2019)
Structural and functional consequences of the STAT5BN642H driver mutation
Elvin D. de Araujo et al.
NATURE COMMUNICATIONS (2019)
STAT5B(N642H) is a driver mutation for T cell neoplasia
Ha Thi Thanh Pham et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Drug-perturbation-based stratification of blood cancer
Sascha Dietrich et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
E. I. Andersson et al.
LEUKEMIA (2018)
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
S. Degryse et al.
LEUKEMIA (2018)
Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
Liye He et al.
CANCER RESEARCH (2018)
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
Bettina Wingelhofer et al.
LEUKEMIA (2018)
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL
A. Schrader et al.
NATURE COMMUNICATIONS (2018)
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia
Patricia Johansson et al.
BLOOD CANCER JOURNAL (2018)
Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review
Waseem Lone et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies
Allison Greenplate et al.
JCO PRECISION ONCOLOGY (2018)
The Genetic Basis of Hepatosplenic T-cell Lymphoma
Matthew McKinney et al.
CANCER DISCOVERY (2017)
Mechanisms and consequences of Jak-STAT signaling in the immune system
Alejandro V. Villarino et al.
NATURE IMMUNOLOGY (2017)
Genetic Characterization of T-PLL Reveals Two Major Biologic Subgroups and JAK3 Mutations as Prognostic Marker
Anna Stengel et al.
GENES CHROMOSOMES & CANCER (2016)
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Daniella M. Schwartz et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
Shuqun Yang et al.
ONCOTARGET (2016)
High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia
Emma I. Andersson et al.
BLOOD (2016)
Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia
Cristina Lopez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas
A. Nicolae et al.
LEUKEMIA (2016)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia
Carmen Vicente et al.
HAEMATOLOGICA (2015)
Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden
Christian Prinz et al.
MOLECULAR CANCER (2015)
Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome
Mark J. Kiel et al.
NATURE COMMUNICATIONS (2015)
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
Can Kucuk et al.
NATURE COMMUNICATIONS (2015)
Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia
Carmen Vicente et al.
HAEMATOLOGICA (2015)
Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib
Mike Wei et al.
BLOOD (2015)
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia
Mark J. Kiel et al.
BLOOD (2014)
JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model
Sandrine Degryse et al.
BLOOD (2014)
Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia
D. Bellanger et al.
LEUKEMIA (2014)
Identification of STAT5A and STAT5B Target Genes in Human T Cells
Takahiro Kanai et al.
PLOS ONE (2014)
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
Hanna L. M. Rajala et al.
BLOOD (2013)
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia
Georg Hopfinger et al.
CANCER (2013)
Mature T-cell Lymphomagenesis Induced by Retroviral Insertional Activation of Janus Kinase 1
Tim Heinrich et al.
MOLECULAR THERAPY (2013)
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
Muhammad Furqan et al.
BIOMARKER RESEARCH (2013)
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route
Claire E. Dearden et al.
BLOOD (2011)
Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ
Geoff M. Gordon et al.
BIOCHEMICAL JOURNAL (2010)
Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor α Homodimers
Tekla Hornakova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers
Eun Goo Jeong et al.
CLINICAL CANCER RESEARCH (2008)
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Elisabetta Flex et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia
Marco Herling et al.
BLOOD (2008)
T-cell prolymphocytic leukemia: A single-institution experience
Farhad Ravandi et al.
CLINICAL LYMPHOMA & MYELOMA (2005)
The JAK/STAT signaling pathway
JS Rawlings et al.
JOURNAL OF CELL SCIENCE (2004)
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories
M Herling et al.
BLOOD (2004)
分享论文
